Crossmark Global Holdings Inc. Sells 197 Shares of Insulet Co. (NASDAQ:PODD)

Crossmark Global Holdings Inc. trimmed its position in shares of Insulet Co. (NASDAQ:PODD) by 6.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,936 shares of the medical instruments supplier’s stock after selling 197 shares during the period. Crossmark Global Holdings Inc.’s holdings in Insulet were worth $767,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in PODD. Integrated Wealth Concepts LLC raised its position in shares of Insulet by 1.7% during the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock valued at $596,000 after buying an additional 42 shares during the last quarter. Glenmede Trust Co. NA lifted its position in shares of Insulet by 2.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock worth $484,000 after acquiring an additional 47 shares during the period. Graypoint LLC grew its holdings in shares of Insulet by 5.3% during the 4th quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock worth $243,000 after purchasing an additional 47 shares in the last quarter. Wedmont Private Capital increased its position in shares of Insulet by 3.5% during the third quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier’s stock valued at $326,000 after purchasing an additional 48 shares during the period. Finally, OVERSEA CHINESE BANKING Corp Ltd raised its stake in shares of Insulet by 4.7% in the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,076 shares of the medical instruments supplier’s stock valued at $250,000 after purchasing an additional 48 shares in the last quarter.

Insider Activity

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Insulet Stock Performance

PODD stock opened at $280.35 on Friday. The stock has a market capitalization of $19.66 billion, a PE ratio of 48.01, a price-to-earnings-growth ratio of 3.50 and a beta of 1.22. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a 50 day moving average price of $267.25 and a 200 day moving average price of $235.53. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $282.86.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.13. The business had revenue of $543.90 million for the quarter, compared to analyst estimates of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same quarter in the prior year, the firm posted $0.71 earnings per share. Analysts forecast that Insulet Co. will post 3.22 EPS for the current year.

Analyst Ratings Changes

PODD has been the topic of several analyst reports. Sanford C. Bernstein began coverage on shares of Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target on the stock. JPMorgan Chase & Co. upped their target price on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research note on Thursday, December 12th. Wells Fargo & Company raised their price target on shares of Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. TD Cowen increased their target price on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Finally, Citigroup boosted their price target on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $272.81.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.